SEC Form 4 · accession 0001140361-18-029484
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
Jun 19, 2018
Accepted (ET)
Jun 21, 2018 · 5:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 8, 2018 | G | 5,000 | $0.00 | D | 127,707 | D | |
| Common Stock | Jun 19, 2018 | M | 7,500 | $1.184 | A | 135,207 | D | |
| Common StockF2,F3 | Jun 19, 2018 | S | 2,336 | $176.2016 | D | 132,871 | D | |
| Common StockF2,F4 | Jun 19, 2018 | S | 3,427 | $177.0556 | D | 129,444 | D | |
| Common StockF2,F5 | Jun 19, 2018 | S | 1,737 | $178.1172 | D | 127,707 | D | |
| Common StockF2,F6,F7 | Jun 19, 2018 | S | 8,232 | $177.4359 | D | 41,768 | I | By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 |
| Common StockF2,F8 | Jun 19, 2018 | S | 8,763 | $178.297 | D | 33,005 | I | By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 |
| Common StockF2,F9 | Jun 19, 2018 | S | 3,902 | $179.8333 | D | 29,103 | I | By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 |
| Common StockF2,F10 | Jun 19, 2018 | S | 103 | $180.3368 | D | 29,000 | I | By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 |
| Common Stock | Jun 20, 2018 | M | 28,000 | $1.184 | A | 155,707 | D | |
| Common Stock | Jun 20, 2018 | M | 7,500 | $1.184 | A | 163,207 | D | |
| Common StockF2,F11 | Jun 20, 2018 | S | 2,700 | $178.8052 | D | 160,507 | D | |
| Common StockF2,F12 | Jun 20, 2018 | S | 4,370 | $179.3697 | D | 156,137 | D | |
| Common StockF2,F13 | Jun 20, 2018 | S | 430 | $180.8965 | D | 155,707 | D | |
| Common StockF2,F14 | Jun 20, 2018 | S | 11,336 | $178.9437 | D | 17,664 | I | By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 |
| Common StockF2,F15 | Jun 20, 2018 | S | 9,664 | $179.773 | D | 8,000 | I | By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F17,F16 | $1.184 | Jun 19, 2018 | M | 7,500 | D | — | Nov 14, 2023 | Common Stock | 7,500 | 144,432 | D |
| Employee Stock Option (right to buy)F16 | $1.184 | Jun 20, 2018 | M | 28,000 | D | — | Nov 14, 2023 | Common Stock | 28,000 | 116,432 | D |
| Employee Stock Option (right to buy)F16 | $1.184 | Jun 20, 2018 | M | 7,500 | D | — | Nov 14, 2023 | Common Stock | 7,500 | 108,932 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F10Represents the weighted average sales price per share. The shares sold at prices ranging from $180.23 to $180.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F11Represents the weighted average sales price per share. The shares sold at prices ranging from $178.08 to $179.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F12Represents the weighted average sales price per share. The shares sold at prices ranging from $179.09 to $180.02 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F13Represents the weighted average sales price per share. The shares sold at prices ranging from $180.85 to $180.90 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F14Represents the weighted average sales price per share. The shares sold at prices ranging from $178.50 to $179.48 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F15Represents the weighted average sales price per share. The shares sold at prices ranging from $179.50 to $180.04 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F16The options have fully vested and are immediately exercisable.
- F17Option exercises that were previously reported by the Reporting Person were attributed to a single option grant in each prior Form 4 filed by the Reporting Person with the Securities and Exchange Commission. This Form 4 combines two option grants with identical terms and reports the respective option exercises in the aggregate on one row. The shares reported in this column as beneficially owned following the reported transaction represents the outstanding shares underlying both option grants.
- F2Represents the aggregate of sales effected on the same day at different prices.
- F3Represents the weighted average sales price per share. The shares sold at prices ranging from $175.60 to $176.59 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4Represents the weighted average sales price per share. The shares sold at prices ranging from $176.64 to $177.44 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F5Represents the weighted average sales price per share. The shares sold at prices ranging from $177.67 to $178.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F6Represents the weighted average sales price per share. The shares sold at prices ranging from $177.00 to $177.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F7Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 previously reported as held directly pursuant to Rule 16a-13.
- F8Represents the weighted average sales price per share. The shares sold at prices ranging from $178.03 to $179.00 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F9Represents the weighted average sales price per share. The shares sold at prices ranging from $179.20 to $180.15 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.